Cargando…

Low-cost rapid detection of rifampicin resistant tuberculosis using bacteriophage in Kampala, Uganda

BACKGROUND: Resistance to anti-tuberculosis drugs is a serious public health problem. Multi-drug resistant tuberculosis (MDR-TB), defined as resistance to at least rifampicin and isoniazid, has been reported in all regions of the world. Current phenotypic methods of assessing drug susceptibility of...

Descripción completa

Detalles Bibliográficos
Autores principales: Traore, Hamidou, Ogwang, Sam, Mallard, Kim, Joloba, Moses L, Mumbowa, Francis, Narayan, Kalpana, Kayes, Susan, Jones-Lopez, Edward C, Smith, Peter G, Ellner, Jerrold J, Mugerwa, Roy D, Eisenach, Kathleen D, McNerney, Ruth
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1779803/
https://www.ncbi.nlm.nih.gov/pubmed/17212825
http://dx.doi.org/10.1186/1476-0711-6-1
_version_ 1782131834579058688
author Traore, Hamidou
Ogwang, Sam
Mallard, Kim
Joloba, Moses L
Mumbowa, Francis
Narayan, Kalpana
Kayes, Susan
Jones-Lopez, Edward C
Smith, Peter G
Ellner, Jerrold J
Mugerwa, Roy D
Eisenach, Kathleen D
McNerney, Ruth
author_facet Traore, Hamidou
Ogwang, Sam
Mallard, Kim
Joloba, Moses L
Mumbowa, Francis
Narayan, Kalpana
Kayes, Susan
Jones-Lopez, Edward C
Smith, Peter G
Ellner, Jerrold J
Mugerwa, Roy D
Eisenach, Kathleen D
McNerney, Ruth
author_sort Traore, Hamidou
collection PubMed
description BACKGROUND: Resistance to anti-tuberculosis drugs is a serious public health problem. Multi-drug resistant tuberculosis (MDR-TB), defined as resistance to at least rifampicin and isoniazid, has been reported in all regions of the world. Current phenotypic methods of assessing drug susceptibility of M. tuberculosis are slow. Rapid molecular methods to detect resistance to rifampicin have been developed but they are not affordable in some high prevalence countries such as those in sub Saharan Africa. A simple multi-well plate assay using mycobacteriophage D29 has been developed to test M. tuberculosis isolates for resistance to rifampicin. The purpose of this study was to investigate the performance of this technology in Kampala, Uganda. METHODS: In a blinded study 149 M. tuberculosis isolates were tested for resistance to rifampicin by the phage assay and results compared to those from routine phenotypic testing in BACTEC 460. Three concentrations of drug were used 2, 4 and 10 μg/ml. Isolates found resistant by either assay were subjected to sequence analysis of a 81 bp fragment of the rpoB gene to identify mutations predictive of resistance. Four isolates with discrepant phage and BACTEC results were tested in a second phenotypic assay to determine minimal inhibitory concentrations. RESULTS: Initial analysis suggested a sensitivity and specificity of 100% and 96.5% respectively for the phage assay used at 4 and 10 μg/ml when compared to the BACTEC 460. However, further analysis revealed 4 false negative results from the BACTEC 460 and the phage assay proved the more sensitive and specific of the two tests. Of the 39 isolates found resistant by the phage assay 38 (97.4%) were found to have mutations predictive of resistance in the 81 bp region of the rpoB gene. When used at 2 μg/ml false resistant results were observed from the phage assay. The cost of reagents for testing each isolate was estimated to be 1.3US$ when testing a batch of 20 isolates on a single 96 well plate. Results were obtained in 48 hours. CONCLUSION: The phage assay can be used for screening of isolates for resistance to rifampicin, with high sensitivity and specificity in Uganda. The test may be useful in poorly resourced laboratories as a rapid screen to differentiate between rifampicin susceptible and potential MDR-TB cases.
format Text
id pubmed-1779803
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-17798032007-01-20 Low-cost rapid detection of rifampicin resistant tuberculosis using bacteriophage in Kampala, Uganda Traore, Hamidou Ogwang, Sam Mallard, Kim Joloba, Moses L Mumbowa, Francis Narayan, Kalpana Kayes, Susan Jones-Lopez, Edward C Smith, Peter G Ellner, Jerrold J Mugerwa, Roy D Eisenach, Kathleen D McNerney, Ruth Ann Clin Microbiol Antimicrob Research BACKGROUND: Resistance to anti-tuberculosis drugs is a serious public health problem. Multi-drug resistant tuberculosis (MDR-TB), defined as resistance to at least rifampicin and isoniazid, has been reported in all regions of the world. Current phenotypic methods of assessing drug susceptibility of M. tuberculosis are slow. Rapid molecular methods to detect resistance to rifampicin have been developed but they are not affordable in some high prevalence countries such as those in sub Saharan Africa. A simple multi-well plate assay using mycobacteriophage D29 has been developed to test M. tuberculosis isolates for resistance to rifampicin. The purpose of this study was to investigate the performance of this technology in Kampala, Uganda. METHODS: In a blinded study 149 M. tuberculosis isolates were tested for resistance to rifampicin by the phage assay and results compared to those from routine phenotypic testing in BACTEC 460. Three concentrations of drug were used 2, 4 and 10 μg/ml. Isolates found resistant by either assay were subjected to sequence analysis of a 81 bp fragment of the rpoB gene to identify mutations predictive of resistance. Four isolates with discrepant phage and BACTEC results were tested in a second phenotypic assay to determine minimal inhibitory concentrations. RESULTS: Initial analysis suggested a sensitivity and specificity of 100% and 96.5% respectively for the phage assay used at 4 and 10 μg/ml when compared to the BACTEC 460. However, further analysis revealed 4 false negative results from the BACTEC 460 and the phage assay proved the more sensitive and specific of the two tests. Of the 39 isolates found resistant by the phage assay 38 (97.4%) were found to have mutations predictive of resistance in the 81 bp region of the rpoB gene. When used at 2 μg/ml false resistant results were observed from the phage assay. The cost of reagents for testing each isolate was estimated to be 1.3US$ when testing a batch of 20 isolates on a single 96 well plate. Results were obtained in 48 hours. CONCLUSION: The phage assay can be used for screening of isolates for resistance to rifampicin, with high sensitivity and specificity in Uganda. The test may be useful in poorly resourced laboratories as a rapid screen to differentiate between rifampicin susceptible and potential MDR-TB cases. BioMed Central 2007-01-09 /pmc/articles/PMC1779803/ /pubmed/17212825 http://dx.doi.org/10.1186/1476-0711-6-1 Text en Copyright © 2007 Traore et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Traore, Hamidou
Ogwang, Sam
Mallard, Kim
Joloba, Moses L
Mumbowa, Francis
Narayan, Kalpana
Kayes, Susan
Jones-Lopez, Edward C
Smith, Peter G
Ellner, Jerrold J
Mugerwa, Roy D
Eisenach, Kathleen D
McNerney, Ruth
Low-cost rapid detection of rifampicin resistant tuberculosis using bacteriophage in Kampala, Uganda
title Low-cost rapid detection of rifampicin resistant tuberculosis using bacteriophage in Kampala, Uganda
title_full Low-cost rapid detection of rifampicin resistant tuberculosis using bacteriophage in Kampala, Uganda
title_fullStr Low-cost rapid detection of rifampicin resistant tuberculosis using bacteriophage in Kampala, Uganda
title_full_unstemmed Low-cost rapid detection of rifampicin resistant tuberculosis using bacteriophage in Kampala, Uganda
title_short Low-cost rapid detection of rifampicin resistant tuberculosis using bacteriophage in Kampala, Uganda
title_sort low-cost rapid detection of rifampicin resistant tuberculosis using bacteriophage in kampala, uganda
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1779803/
https://www.ncbi.nlm.nih.gov/pubmed/17212825
http://dx.doi.org/10.1186/1476-0711-6-1
work_keys_str_mv AT traorehamidou lowcostrapiddetectionofrifampicinresistanttuberculosisusingbacteriophageinkampalauganda
AT ogwangsam lowcostrapiddetectionofrifampicinresistanttuberculosisusingbacteriophageinkampalauganda
AT mallardkim lowcostrapiddetectionofrifampicinresistanttuberculosisusingbacteriophageinkampalauganda
AT jolobamosesl lowcostrapiddetectionofrifampicinresistanttuberculosisusingbacteriophageinkampalauganda
AT mumbowafrancis lowcostrapiddetectionofrifampicinresistanttuberculosisusingbacteriophageinkampalauganda
AT narayankalpana lowcostrapiddetectionofrifampicinresistanttuberculosisusingbacteriophageinkampalauganda
AT kayessusan lowcostrapiddetectionofrifampicinresistanttuberculosisusingbacteriophageinkampalauganda
AT joneslopezedwardc lowcostrapiddetectionofrifampicinresistanttuberculosisusingbacteriophageinkampalauganda
AT smithpeterg lowcostrapiddetectionofrifampicinresistanttuberculosisusingbacteriophageinkampalauganda
AT ellnerjerroldj lowcostrapiddetectionofrifampicinresistanttuberculosisusingbacteriophageinkampalauganda
AT mugerwaroyd lowcostrapiddetectionofrifampicinresistanttuberculosisusingbacteriophageinkampalauganda
AT eisenachkathleend lowcostrapiddetectionofrifampicinresistanttuberculosisusingbacteriophageinkampalauganda
AT mcnerneyruth lowcostrapiddetectionofrifampicinresistanttuberculosisusingbacteriophageinkampalauganda